Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold presentations on its lead Radio-DARPin candidate MP0712, co-developed with Orano Med, at two upcoming scientific conferences, including the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Theranostics Conference, taking place November 4–7 in Bethesda, MD, USA and the IASLC/ASCO 2026 North America Conference on Lung Cancer (NACLC), taking place December 4–6 in Scottsdale, AZ, USA.

Details of the presentations

2026 SNMMI Theranostics Conference

Title: How much Target Expression is Enough? Learnings from advancing MP0712, a DLL3 Radio-DARPin for SCLC, into the clinic
Format: Oral presentation
Presenter: Daniel Steiner, Ph.D., SVP Targeted Radio Therapeutics
Session: Future of Theranostics – Part 1
Date and time: Saturday, November 7, 8:40 – 9:00 am EST
Location: Bethesda North Marriott Hotel & Conference Center, Bethesda, Maryland

NACLC 2026

Title: [²¹²Pb]Pb-MP0712 in patients with small cell lung cancer (SCLC) and other Delta-like ligand 3 (DLL3) expressing solid tumors: Initial dose escalation data from a first-in-human Phase 1/2a study
Format: Poster presentation
Presenting author: Ticiana Leal, M.D., Winship Cancer Institute of Emory University, Atlanta, GA
Date and time: Saturday, December 5, 2026, 4:15 – 5:45 pm MST
Location: Grand Hyatt Scottsdale Resort, Scottsdale, Arizona

The presentations will be made available on Molecular Partners’ website after the presentations.